Results 261 to 270 of about 101,286 (277)

An update on the immune landscape in lung and head and neck cancers

Ca-A Cancer Journal for Clinicians, 2020
Jennifer W Carlisle, Taofeek Kunle Owonikoko, Nabil F Saba   +2 more
exaly  

Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial

Nature Medicine, 2023
Tina Cascone, Sreyashi Basu, Ansam Sinjab   +2 more
exaly  

Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial

Nature Medicine, 2020
Nick van Dijk, Alberto Gil-Jimenez, Karina Silina   +2 more
exaly  

A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma

Nature Medicine, 2021
Julie Westerlin Kjeldsen, Evelina Martinenaite, Eva Ellebaek   +2 more
exaly  

First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial

Lancet, The, 2021
Arnaud Scherpereel, Anna K Nowak, Nobukazu Fujimoto   +2 more
exaly  

Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial

Nature Medicine, 2023
John M Kirkwood, Christoph Hoeller, Tarek M Meniawy   +2 more
exaly  

Nivolumab

Reactions Weekly
  +4 more sources

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma

Journal of Clinical Oncology, 2022
Jedd D Wolchok, Vanna Chiarion Sileni, Jean-Jacques Grob   +2 more
exaly  

Hodgkin lymphoma: A review and update on recent progress

Ca-A Cancer Journal for Clinicians, 2018
Satish P Shanbhag, Richard F Ambinder
exaly  

Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma

Nature Medicine, 2019
Kurt A Schalper, Susana Inogés, Sonia Tejada   +2 more
exaly